Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization

Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization

Background & Aims: Herein we used data derived from the SORAMIC trial to explore the predictive value of systemic inflammatory markers (neutrophil-to-lymphocyte ratio [NLR] and platelet-to-lymphocyte ratio [PLR]) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib...

Full description

Bibliographic Details
Main Authors: Osman Öcal, Melanie Alexandra Kimm, Thi Phuong Thao Hoang, Maciej Pech, Elif Öcal, Najib Ben Khaled, Bruno Sangro, Jens Ricke, Max Seidensticker, Moritz Wildgruber
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:JHEP Reports
Subjects:
Hepatocellular carcinoma
Sorafenib
Radioembolization
Platelet-to-lymphocyte ratio
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923003269

Internet

http://www.sciencedirect.com/science/article/pii/S2589555923003269

Similar Items